JP2023540484A - Simple opening device for drug storage cartons - Google Patents

Abstract

A drug storage carton includes a bottom box and a lid. The bottom box includes a bottom wall, a first side wall, a second side wall, a back wall, and a front wall. The carton also includes a lid coupled to the bottom box and movable between an open position and a closed position. The bottom box is closed by the lid when the lid is in the closed position. Additionally, the carton includes a release tab that includes a portion of the lid and one of the second front wall and is defined by a perforation line in the lid and one of the bottom box. The carton may also include an adhesive disposed over at least a portion of the release tab to selectively bond the lid and bottom box. When the lid is in the closed position, the release tab is secured to one of the lid and bottom box via the perforation line and to the other of the lid and bottom box via adhesive. Alternatively, when the lid is in the open position, the release tab is separated from one of the lid and the bottom box along the perforation line and fixed to the other of the lid and the bottom box via adhesive.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Patent Application No. 63/073,800, filed September 2, 2020. The priority application is incorporated herein by reference.

TECHNICAL FIELD This disclosure relates to drug storage cartons and, more particularly, to storage cartons.

Many drug storage cartons are used to store personal drug doses for home use. These storage cartons are often constructed to hold one, two, three, four, or more drug doses. Cartons used to store drug doses must be sealed to prevent tampering of the contents of the carton before first use by an individual. As a result, most drug storage cartons are sealed with tamper-evident seals, such as closure labels, and tampering with the closure label will result in damage to the carton.

Medication storage containers using tamper-evident seals can be difficult to open without using cutting tools or damaging the package. Cutting tools can be dangerous to use, and in some cases, damage to the carton leaves drug doses stored within the carton exposed to the outside environment. These drug storage cartons are more secure and can provide clear evidence of tampering, but can be difficult to open.

The present disclosure is directed to cartons for drug storage. The carton includes a bottom box having a bottom wall, a first side wall, a second side wall, a back wall, and a front wall. The carton also includes a lid hinged to the rear wall between an open position and a closed position, the lid having a third side wall adjacent the first side wall, a fourth side wall adjacent the second side wall. , and a second front wall adjacent the first front wall. Furthermore, the bottom box is disposed within the third side wall, the fourth side wall, and the second front wall when the lid is in the closed position. The carton also includes a portion of the second front wall and includes a release tab defined between the bottom edge of the second front wall and the perforation line of the second front wall. The release tab is also secured to the bottom box when the lid is in the open and closed positions. Further, when the lid is in the open position, the release tab is separated from the second front wall along the perforation line.

The present disclosure is directed to cartons for drug storage. The carton includes a bottom box having a bottom wall, a first side wall, a second side wall, a back wall, and a front wall. The carton also includes a lid hinged to the rear wall between an open position and a closed position, the lid having a third side wall adjacent the first side wall, a fourth side wall adjacent the second side wall. , and a second front wall adjacent the first front wall. Furthermore, the bottom box is disposed within the third side wall, the fourth side wall, and the second front wall when the lid is in the closed position. The carton also includes a portion of the second front wall and includes a release tab defined between the bottom edge of the second front wall and the perforation line of the second front wall. The release tab is also secured to the bottom box via the adhesive label when the lid is in the open and closed positions. Further, when the lid is in the open position, the release tab is separated from the second front wall along the perforation line.

It is believed that the following description, taken in conjunction with the accompanying drawings, will provide a better understanding of the present disclosure. In some drawings, elements may be selectively omitted and simplified to more clearly show other elements. The omission of such elements in some drawings does not necessarily represent the presence or absence of particular elements in any of the exemplary embodiments, unless explicitly stated in the corresponding written description. Additionally, the drawings are not necessarily to scale.

FIG. 3 is a top view of a die cut of a drug storage carton including an easy-open push feature. FIG. 2 is a perspective view of a drug storage carton including the easy-open feature of FIG. 1; FIG. 3 is a plan view of an easy-open feature including a release tab forming a push-open feature. FIG. 3 is a perspective view of the drug storage carton of FIG. 2 further including a closure label for sealing the drug storage carton. 3 is a perspective view of the drug storage carton of FIG. 2 with the easy-open feature pressed; FIG. 3 is a perspective view of the medication storage carton of FIG. 2 with the easy-open feature removed from the outer front wall; FIG. FIG. 3 is a top view of a die cut of a medication storage carton including an easy-open push-and-pull feature. FIG. 8 is a perspective view of a medication storage carton including the easy-open feature of FIG. 7; 8 is a plan view of the easy opening feature of FIG. 7, including a release tab forming a push and pull opening feature; FIG. 8 is a perspective view of the drug storage carton of FIG. 7 further including a closure label for sealing the drug storage carton; FIG. 8 is a perspective view of the drug storage carton of FIG. 7 with the push-and-pull easy-open feature pressed; FIG. 9 is a perspective view of the medication storage carton of FIG. 8 with the easy-open feature removed from the outer front wall; FIG. FIG. 7 is a top view of an alternative drug storage carton die cut with an easy-open push feature. 14 is a perspective view of the alternative drug storage carton of FIG. 13 with an easy-open push feature. FIG.

Those skilled in the art will appreciate that elements in the figures are drawn for simplicity and clarity and are not necessarily drawn to scale. For example, the dimensions and/or relative positions of some of the elements in the figures may be exaggerated relative to other elements to improve understanding of various embodiments of the invention. Additionally, common but well-understood elements useful or necessary in commercially viable embodiments may not be shown in order to unobtrusively illustrate the various embodiments. many. Furthermore, while it will be appreciated that certain acts and/or steps may be described or shown in a particular order of occurrence, one of ordinary skill in the art will appreciate that such specificity as to order is in practice. You will understand that this is not necessary. Terms and expressions used herein have their ordinary technical meanings as given to such terms and expressions by one of ordinary skill in the art, as described above, unless a different specific meaning is provided herein. It will also be understood that it has.

Medication storage cartons store and protect doses of medications for home use. One such drug storage carton includes a lidded carton. A lidded carton may include, for example, a top-lid carton (ie, a carton with a top lid) or a bottom-lid carton (i.e., a carton with a bottom lid). Such a carton may include a bottom box hinged to a lid having side and front walls that overlap side and front walls of the bottom box. These cartons are useful for protecting drug doses during transportation and also for protecting drugs from tampering. These cartons are protected from tampering because the carton is sealed with a tamper-evident seal. As a result, a carton with a broken seal or damaged exterior indicates that the contents of the carton have been tampered with and the drug may be unsafe for use. However, while the security provided by tamper-evident seals is important, it makes drug storage cartons difficult to open.

The easy opening device for drug storage cartons of the present disclosure provides improved security while also making the drug storage containers user friendly and highly accessible. For example, instead of requiring a user to tear open a carton to access medication or use a sharp cutting tool to cut a tamper-evident seal, the carton is protected from all tampering during transportation and storage. An easy-open feature can be included that allows the drug storage carton to be easily opened while maintaining the integrity of the tamper-evident seal.

The disclosed device includes providing a release tab on the front wall of the lid. This release tab disengages from the front wall and separates the tamper-evident label attached to both the release tab and the bottom of the storage carton from the front wall of the lid, allowing the medication storage carton to be opened. be able to. As a result, the user can detach the release tab away from the front wall of the lid without having to cut the closure label or disassemble the storage carton. The storage carton of the present disclosure further includes a tab disposed on the bottom box of the storage carton to enable the storage carton to be selectively closed after the closure label is removed from the lid.

The devices of the present disclosure can be incorporated into any carton style or design. Such carton designs include, but are not limited to, open face cartons slidably received within and surrounded by a carton sleeve, cartons with removable tops, sealable cylinders, etc. Not done. For example, a device of the present disclosure can include providing one or more release tabs on the drug storage carton. For example, instead of a hinged lidded carton, the drug storage carton may include a bottom box and a top box that is separate from the bottom box. In such an example, the top box may include first and second release tabs and a closure label for each release tab. As a result, the user can separate the first and second release tabs from the upper box. Accordingly, release tabs can be incorporated into any carton style or design.

FIG. 1 is a top view of a die cut 100 of a drug storage carton 102 that includes an easy-open feature 104. FIG. Carton 102 is made from a single piece of material. For example, carton 102 may be made from paperboard, cardboard, mount, or similar material. However, carton 102 may be made from multiple pieces that are glued or otherwise secured together. Carton 102 includes multiple fold lines 106 that divide carton 102 into multiple walls and flaps. When each of the plurality of folding lines 106 is folded, the carton 102 forms a box-shaped carton.

Carton 102 includes a bottom box 110 having a bottom wall 112, a first side wall 114, a second side wall 116; a back wall 118, and a first front wall 120. The rear wall includes flaps 122a and 122b, and the first front wall 120 includes flaps 124a and 124b. When each of the first side wall 114, the second side wall 116, the back wall 118, and the first front wall 120 are folded, flaps 122a and 124a are adhered to the first side wall 114, and flaps 122b and 124b are attached to the first side wall 114. 2 side wall 116. Alternatively, the flaps 122a, 122b, 124a, 124b may be secured to the first and second side walls 114, 116 via interlocking slits, other adhesives, or other known methods of assembling boxes and cartons. . As a result, first side wall 114 , second side wall 116 , rear wall 118 , and first front wall 120 are all secured together to form bottom box 110 .

Additionally, first front wall 120 includes a first tab 126a and a second tab 126b. Additionally, first front wall 120 includes a reduced material portion 128 . The reduced material portion 128 increases the flexibility of the first front wall 120 compared to the first front wall 120 if the first front wall 120 did not include the reduced material portion 128.

Additionally, carton 102 includes a lid 140 hinged to rear wall 118. This version of the lid 140 is a top lid and includes a top wall 142, a third side wall 144, a fourth side wall 146, and a second front wall 148. The third sidewall 144 includes a flap 152a and the fourth sidewall includes a flap 152b. Flaps 152a and 152b are adhered to second front wall 148 when third side wall 144, fourth side wall 146, and second front wall 148 are folded. The flaps 152a, 152b may be secured to the first and second side walls 114, 116 via interlocking slits, other adhesives, or other known methods of assembling boxes and cartons. As a result, when the third side wall 144, fourth side wall 146, and second front wall 148 for the lid 140 are assembled, the first side wall 114, the second side wall 116, and the first front wall 120 The bottom box 110 containing the bottom box 110 is covered.

The second front wall 148 includes a perforation line 160 about a release tab 162 adjacent a bottom edge 164 of the second front wall 148 . Release tab 162 is surrounded by perforation line 160 and bottom edge 164. As shown in FIG. 1, release tab 162 includes a first kiss cut 166 and bottom wall 112 includes a second kiss cut 168. Perforation line 160 allows release tab 162 to disengage from second front wall 148 when sufficient force is applied to release tab 162 . Although the release tab 162 is partially rectangular with rounded sides as shown in FIG. It may be

In some examples, the second front wall 148 may include latching features 154a and 154b when the flaps 152a and 152b are adhered to the second front wall 148. When carton 102 is assembled, tab sheet 154a receives tab 126a and tab sheet 154b receives tab 126b. As a result, tab 126a rests on tab sheet 154a, thereby providing resistance when opening carton 102. Further, when carton 102 is closed, tab 126a moves to a position with tab sheet 154a, thereby producing an audible click indicating that the carton is closed. Although carton 102 in FIG. 1 is shown as having two tabs, tabs 126a and 126b, carton 102 can include more or less than two tabs.

FIG. 2 is a perspective view of a drug storage carton 202 including a storage cavity 210 and the easy-open feature 104 of FIG. As shown in FIG. 2, the carton 202 is folded and assembled based on the die cut 100 such that the storage cavity 210 can receive and store a drug delivery device 212 containing a drug, as shown in FIG. It will be done. Therefore, the bottom box 110 is placed within the lid 140. As a result, first sidewall 114 is adjacent to third sidewall 144 and second sidewall 116 is adjacent to fourth sidewall 146. Further, as shown in FIG. 2, the second front wall 148 is an outer front wall with a bottom edge 164 adjacent the bottom wall 112.

In accordance with the present disclosure, carton 202 is designed to store at least one drug delivery device 212 within a storage cavity 210 located in bottom box 110. Although carton 202 is shown as having one drug delivery device 212, in other examples, carton 202 can store one, two, or more drug delivery devices. Drug delivery device 212 can be a prefilled hypodermic syringe or a prefilled autoinjector product for use with a drug autoinjector.

Bottom box 110 further includes tabs 126a and 126b located on first front wall 120. Tab 126a engages a flap 152a that is hinged to the third side wall 144, and tab 126b engages a flap 152b that is hinged to the fourth side wall 146. As a result, carton 202 may be secured in the closed position when tabs 126a and 126b engage latching features 154a and 154b, such as flaps 152a and 152b, respectively.

FIG. 3 is a top view of the easy-open feature 104, including the release tab 162 that makes up the easy-open feature 104. As shown in FIG. Release tab 162 is partially surrounded by perforation line 160. Perforation line 160 is made up of a series of cuts 302. The length of cut 302 shown in FIG. 3 may be longer or shorter. Additionally, although five cuts 302 are shown, the perforation line may be comprised of more or fewer cuts 302. Additionally, release tab 162 includes a first kiss cut 166. The first kiss cut 166 is a partial cut through the release tab 162. The partial cut improves the bond between the release tab 162 and the tamper-evident seal by increasing the surface area to which the tamper-evident seal can adhere. Although the first kiss cut 166 is in the shape of a triangular wave, the first kiss cut 166 can be any of a variety of shapes or patterns.

FIG. 4 is a perspective view of the drug storage carton 202 of FIG. 2 further including a closure label 402 for sealing the drug storage carton 202. Closing label 402 functions as a tamper-evident seal. Any attempt to peel closure label 402 from carton 202 will result in visible damage to carton 202 and/or closure label 402. Thus, by being aware of such evidence of tampering, a person can avoid using medication stored in a potentially tampered carton.

As shown in FIG. 4, release tab 162 is secured to bottom wall 112 via closure label 402. The release tab 162 is connected to the second front wall 148, thereby securing the lid 140 in the closed position. Alternatively, the release tab 162 is secured to the first front wall 120 of the bottom box 110 via an adhesive disposed between the release tab 162 and the first front wall 120. However, in both examples, the lid 140 is secured closed via a closure label 402 or adhesive that is applied only to the lid 140 within the release tab 162. Additionally, the adhesive or closure label 402 may be applied to a substantial portion of the release tab 162, including along or adjacent the perforation line 160 of the release tab 162. For example, adhesive or closure label 402 can have a similar shape and size as release tab 162. In such instances, the adhesive or closure label 402 concentrates the force exerted on the release tab 162 onto the perforation line 160. Accordingly, the adhesive or closure label 402 covering substantially all of the release tab makes it easier to remove the release tab 162 from the second front wall 148.

Additionally, closure label 402 is positioned above first kiss-cut 166 and second kiss-cut 168. As a result, closure label 402 has a strong adhesive bond with both release tab 162 and bottom wall 112. Thus, tampering with closure label 402 will result in visible and obvious tampering and/or damage. Thus, closure label 402 provides security in the integrity of the medication stored within carton 202.

Although not shown in FIG. 4, in some embodiments, the carton 202 includes a first exterior finish with a first texture, and the release tab 162 includes a second exterior finish with a second texture. Including finishing. The first texture is different from the second texture so that the user can feel the approximate location of the release tab 162 and closure label 402. As a result, the difference between the first texture and the second texture improves the accessibility and usability of the storage carton 202. In some examples, the first texture may be a wax or varnish that protects the information printed on the exterior surface of the carton 202. In contrast, the second texture may be less treated to improve the adhesion between the closure label 402 and the carton 202 to improve the security of the tamper-evident seal.

FIG. 5 is a perspective view of the medication storage carton of FIG. 2 with the easy-open feature 104 pressed. As shown in FIG. 5, the user can hold the carton 202 with one hand while pressing the easy-open feature 104. However, the carton 202 may be too large to open with one hand, and it may be necessary to hold the carton 202 with one hand while pressing the easy-open feature 104 with the other hand.

According to the present disclosure, the release tab 162 is a carton opening feature 104 that causes the release tab 162 to disengage from the second front wall 148. Release tab 162 functions as a push tab to release release tab 162 from second front wall 148 . Because closure label 402 is adhered only to bottom wall 112 and release tab 162, second front wall 148 is no longer maintained in the closed position by closure label 402.

As described with respect to FIG. 1, first front wall 120 includes a cutout 128. The cutouts increase the flexibility of the first front wall 120 relative to the second front wall 148. The increased flexibility of the first front wall 120 increases the distance that the release tab 162 can move. Because the first front wall 120 has increased flexibility, the release tab 162 can be moved further and is easier to disengage from the second front wall 148. Additionally, the first front wall 120 has a cutout 128, but the material of the first front wall 120 is such that the interior environment of the carton 202 remains isolated from the exterior environment of the carton 202 when the carton 202 is closed. It should be taller than the release tab 162 so that it is.

FIG. 6 is a perspective view of the medication storage carton 202 of FIG. 2 with the easy-open feature 104 removed from the second front wall 148. With release tab 162 disengaged from second front wall 148, lid 140 can be both opened and closed. In the open position, the lid 140 does not cover the bottom box 110. In contrast, the lid 140 covers the bottom box 110 when in the closed position. Further, in the closed position, tabs 126a and 126b engage latching features 154a and 154b, such as flaps 152a and 152b, to removably secure lid 140 in the closed position.

FIG. 7 is a top view of a die cut 700 of a medication storage carton 702 that includes an easy-open push-and-pull feature 704. Carton 702 is made from a single piece of material. For example, carton 702 may be made from paperboard, cardboard, mount, or similar material. Additionally, carton 702 includes a plurality of fold lines 706 that divide carton 702 into a plurality of walls and flaps. When each of the plurality of folding lines 706 is folded, the carton 702 forms a box-shaped carton.

Carton 702 includes a bottom box 710 having a bottom wall 712, a first side wall 714, a second side wall 716; a back wall 718, and a first front wall 720. The rear wall includes flaps 722a and 722b, and the first front wall 720 includes flaps 724a and 724b. When each of the first side wall 714, the second side wall 716, the back wall 718, and the first front wall 720 are folded, flaps 722a and 724a are adhered to the first side wall 714, and flaps 722b and 724b are attached to the first side wall 714, and the flaps 722b and 724b are 2 side wall 716. Alternatively, the flaps 722a, 722b, 724a, 724b may be secured to the first and second side walls 714, 716 via interlocking slits, other adhesives, or other known methods of assembling boxes and cartons. . As a result, first side wall 714 , second side wall 716 , back wall 718 , and first front wall 720 are all secured together to form bottom box 710 .

Additionally, first front wall 720 includes a first tab 726a and a second tab 726b. First front wall 720 includes a reduced material portion 728 . The reduced material portion 728 increases the flexibility of the first front wall 720 compared to the first front wall 720 if the first front wall 720 did not include the reduced material portion 728.

Additionally, carton 702 includes a lid 740 hinged to rear wall 718. This version of the lid 740 is a top lid and includes a top wall 742, a third side wall 744, a fourth side wall 746, and a second front wall 748. The third sidewall 744 includes a flap 752a and the fourth sidewall includes a flap 752b. Flaps 752a and 752b are adhered to second front wall 748 when third side wall 744, fourth side wall 746, and second front wall 748 are folded. The flaps 752a, 752b may be secured to the first and second side walls 714, 716 via interlocking slits, other adhesives, or other known methods of assembling boxes and cartons. In some examples, the second front wall 748 can include latching features 754a and 754b when the flaps 752a and 752b are adhered to the second front wall 748. As a result, when the third side wall 744, fourth side wall 746, and second front wall 748 for the lid 740 are assembled, the first side wall 714, the second side wall 716, and the first front wall 720 The bottom box 710 containing the bottom box 710 is covered.

The second front wall 748 includes a perforation line 760 around a release tab 762 adjacent a bottom edge 764 of the second front wall 748 . Release tab 762 is surrounded by perforation line 760 and bottom edge 764. Release tab 762 includes a push tab 770 and a pull tab 772. Push tab 770 and pull tab 772 are separated by fold line 774. As a result, push tab 770 is hinged to pull tab 772. As shown in FIG. 7, release tab 762 also includes a kiss cut 780.

In some examples, the second front wall 748 can include latching features 754a and 754b when the flaps 752a and 752b are adhered to the second front wall 748. When carton 702 is assembled, tab sheet 754a receives tab 726a and tab sheet 754b receives tab 726b. As a result, tab 726a rests on tab sheet 754a, thereby providing resistance when opening carton 702. Additionally, when carton 702 is closed, tab 726a moves into position with tab sheet 754a, thereby producing an audible click indicating that the carton is closed. Although carton 702 in FIG. 7 is shown as having two tabs, tabs 726a and 726b, carton 702 can include more or less than two tabs.

FIG. 8 is a perspective view of a drug storage carton 802 including the easy-open feature 704 of FIG. As shown in FIG. 8, carton 802 is a folded carton 702 of die cut 700 as shown in FIG. As shown in FIG. 8, bottom box 710 is placed within lid 740. As a result, first sidewall 714 is adjacent to third sidewall 744 and second sidewall 716 is adjacent to fourth sidewall 746. Further, as shown in FIG. 8, the second front wall 748 is an outer front wall with a bottom edge 764 adjacent the bottom wall 712.

In accordance with the present disclosure, carton 802 is designed to store at least one drug delivery device 812 within a storage cavity 810 located in bottom box 710. Although carton 802 is shown as having one drug delivery device 812, in other examples, carton 802 can store one, two, or more drug delivery devices. Drug delivery device 812 can be a prefilled hypodermic syringe or a prefilled autoinjector product for use with a drug autoinjector.

Bottom box 710 further includes tabs 726a and 726b located on first front wall 720. Tab 726a engages a flap 752a that is hinged to the third side wall 744, and tab 726b engages a flap 752b that is hinged to the fourth side wall 746. As a result, carton 802 may be secured in the closed position when tabs 726a and 726b are engaged with 752a and 752b, respectively.

9 is a top view of the easy-open feature 704 of FIG. 7, including the release tab 762 that makes up the easy-open feature 704. FIG. Release tab 762 is partially surrounded by perforation line 760. Perforation line 760 is comprised of a series of cuts 902. The length of the cut 902 shown in FIG. 9 may be longer or shorter. Additionally, although five cuts 902 are shown, the perforation line may be comprised of more or fewer cuts 302. Additionally, release tab 762 includes a kiss cut 780. Kiss cut 780 is a partial cut through release tab 762. The partial cut improves the bond between the release tab 762 and the tamper-evident seal by increasing the surface area to which the tamper-evident seal can adhere. Although the kiss cut 766 is triangular shaped, the first kiss cut 166 can be any of a variety of shapes or patterns.

FIG. 10 is a perspective view of the drug storage carton 802 of FIG. 7 further including a closure label 1002 for sealing the drug storage carton 802. Closing label 1002 functions as a tamper-evident seal. Any attempt to peel closure label 1002 from carton 802 will result in visible damage to carton 802. Thus, a person can avoid using medication stored in a carton that may have been tampered with.

As shown in FIG. 10, release tab 762 is secured to bottom wall 712 via closure label 1002. Release tab 762 is connected to second front wall 748 to secure lid 740 closed. Alternatively, the release tab 762 is secured to the first front wall 720 of the bottom box 710 via an adhesive disposed between the release tab 762 and the first front wall 720. However, in both examples, the lid 740 is secured closed via a closure label 1002 or adhesive applied only to the lid 740 within the release tab 762. Further, the adhesive or closure label 1002 may be applied to a substantial portion of the release tab 762, including being applied along or adjacent the perforation line 760 of the release tab 762. For example, the adhesive or portion of closure label 1002 can have a similar shape and size as release tab 762. In such instances, the adhesive or closure label 1002 concentrates the force exerted on the release tab 762 onto the perforation line 760. Accordingly, the adhesive or closure label 1002 covering substantially all of the release tab 762 makes it easier to remove the release tab 762 from the second front wall 748.

Closure label 1002 is placed above kiss cut 780. As a result, closure label 1002 has a strong adhesive bond with release tab 762. Therefore, tampering with closure label 1002 will result in visible and obvious tampering. Thus, the closure label 1002 provides security in the integrity of the medication stored in the carton 802.

Although not shown in FIG. 10, in some examples, the carton 802 includes a first exterior finish with a first texture, and the release tab 762 includes a second exterior finish with a second texture. Including finishing. The first texture is different from the second texture so that the user can feel the approximate location of the release tab 762 and closure label 1002. As a result, the difference between the first texture and the second texture improves the accessibility and usability of the storage carton 802. In some examples, the first texture may be a wax or varnish that protects the information printed on the exterior surface of the carton 802. In contrast, the second texture may be less treated to improve the adhesion between the closure label 1002 and the carton 802 to improve the security of the tamper-evident seal.

FIG. 11 is a perspective view of the drug storage carton of FIG. 7 during operation of the push and pull easy opening feature; As shown in FIG. 11, the user can hold the carton 802 with one hand while pressing the easy-open feature 704. However, the carton 802 may be too large to open with one hand, and it may be necessary to hold the carton 802 with one hand while pressing the easy-open feature 704 with the other hand.

According to the present disclosure, the release tab 762 is a carton opening feature 704 that causes the release tab 762 to disengage from the second front wall 748. Release tab 762 includes a push tab 770 that disengages a first portion of release tab 762 from second front wall 748 . The user can then fold the release tab 762 about the fold line 774 and pull the pull tab 772 to completely disengage the release tab 762 from the second front wall 748. Because closure label 1002 is adhered only to bottom wall 712 and release tab 762, second front wall 748 is no longer maintained in the closed position by closure label 1002.

As described with respect to FIG. 7, the first front wall 720 includes a cutout 728 for increasing the flexibility of the first front wall relative to the second front wall. Including cutouts. The increased flexibility of the first front wall 720 increases the distance that the release tab 762 can move. Because the first front wall 720 has increased flexibility, the release tab 762 can be moved further and is easier to disengage from the second front wall 748. Additionally, the first front wall 720 has a cutout 728, but the material of the first front wall 720 allows the interior environment of the carton 802 to remain isolated from the exterior environment of the carton 802 when the carton 802 is closed. It should be taller than the release tab 762 so that it is.

FIG. 12 is a perspective view of the medication storage carton 802 of FIG. 8 with the easy-open feature 704 removed from the second front wall 748. With release tab 762 disengaged from second front wall 748, lid 740 can be both opened and closed. In the open position, the lid 740 does not cover the bottom box 710. In contrast, the lid 740 covers the bottom box 710 when in the closed position. Additionally, in the closed position, tabs 726a and 726b engage latching features 754a and 754b, such as flaps 752a and 752b, to removably secure lid 740 in the closed position.

FIG. 13 is a top view of a die cut 1300 of an alternative medication storage carton 1302 that includes an easy-open feature 1304. Carton 1302 may be made from a unitary material such as paperboard, cardboard, mount, or similar material. Additionally, the carton may be made from multiple pieces that are glued or otherwise secured together. As shown, die cut 1300 includes multiple fold lines 1306 that divide carton 1302 into multiple walls and flaps. When each of the plurality of fold lines 1306 is folded, the carton 1302 forms a box-shaped carton.

Carton 1302 includes a bottom wall 1312, a first side wall 1314, a second side wall 1316, a back wall 1318, and a front wall 1320. First sidewall 1314 includes flaps 1322a and 1322b, and second sidewall 1316 includes flaps 1324a and 1324b. Flaps 1322b and 1324b are adhered to bottom wall 1312 when each of first side wall 1314, second side wall 1316, back wall 1318, and front wall 1320 are folded. Alternatively, flaps 1322b and 1324b may be secured to bottom wall 1312 via interlocking slits, other adhesives, or other known methods of assembling boxes and cartons. As a result, the first side wall 1314, the second side wall 1316, the back wall 1318, and the first front wall 1320 are all secured together to form the bottom box 1330 (shown in FIG. 14) of the carton 1302. Form.

Additionally, carton 1302 includes a lid 1340 hinged to rear wall 1318. As shown in FIG. 13, lid 1340 is a lower lid and includes a top wall 1342. As shown in FIG. Top wall 1342 includes a front lid 1346 hinged thereto. When the lid 1340 of the carton 1302 is placed in the closed position (see FIG. 14), the top wall 1342 covers the inwardly folded flaps 1322a and 1322b (see also FIG. 14). Further, in this configuration, the front lid 1346 of the lid 1340 is folded and positioned adjacent the rear of the front wall 1320. Front wall 1320 also defines a release tab 1350 located on its upper edge. Release tab 1350 in this version may be defined by perforation line 1352 in front wall 1320. Perforation line 1352 allows release tab 1350 to separate from the remainder of front wall 1320 under the application of sufficient force. As shown in FIG. 13, release tab 1350 has generally straight sides and a curved bottom, similar to release tab 162 of FIG. 1 (similar to release tabs depicted in previous embodiments). It is roughly U-shaped. In some examples, the drug storage carton may further include one or more kiss cuts 1354 similar to kiss cuts 166, 168 to improve the adhesion of the adhesive used to close the carton 1302.

FIG. 14 is a perspective view of the alternative medication storage carton 1302 of FIG. 13 in its fully assembled/constructed configuration with the lid 1340 in a closed position. As shown, drug storage carton 1302 includes a bottom box 1330 and a lid 1340, shown as a bottom lid. This means that the carton 1302 shown in the closed position in FIG. 14 includes a front lid 1346 located inside the bottom box 1330 and behind the front wall 1320. Carton 1302 further includes a release tab 1350 defined by front wall 1320. Finally, adhesive, in this version an adhesive label 1410, is applied on the corner where the lid 1340 meets the front wall 1320, and a portion of the label 1410 is adhered to the release tab 1350 and the top wall 1342 of the lid 1340. . As a result, when sufficient force is applied to the release tab 1350, the release tab 1350 separates from the front wall 1320 and the lid 1340 then hinges upwardly, bringing the release tab 1350 and label 1410 together into the open position. becomes possible to carry. Thus, in the closed position, the adhesive label 1410 and release tab 1350 keep the lid 1340 fixed in the closed position, but after the release tab 1350 is separated from the front wall 1320, the lid 1340 is in its open position. Move freely.

Further, in some examples, the adhesive or adhesive label 1410 is applied to a substantial portion of the release tab 1350, including being applied along or adjacent the perforation line 1352 of the release tab 1350. obtain. For example, adhesive or a portion of adhesive label 1410 may have a similar shape and size as release tab 1350. In such an example, the adhesive or adhesive label 1410 concentrates the force exerted on the release tab 1350 onto the perforation line 1352. Accordingly, the adhesive or adhesive label 1410 covering substantially all of the release tab 1350 makes it easier to remove the release tab 1350 from the front wall 1320.

The above description describes various devices, assemblies, components, subsystems, and methods of use related to drug delivery devices. The device, assembly, component, subsystem, method, or drug delivery device may further include or contain agents including, but not limited to, the agents specified below, and their generic and biosimilar equivalents. Can be used with. As used herein, the term drug may be used interchangeably with other similar terms, including traditional and non-traditional drugs, nutraceuticals, supplements, biological products, biological to refer to any type of drug or therapeutic material, including clinically active agents and compositions, large molecules, biosimilars, biological equivalents, therapeutic antibodies, polypeptides, proteins, small molecules, and generic drugs. can be used for. Non-therapeutic injectable materials are also included. The drug may be in liquid form, lyophilized, or reconstituted from lyophilized form. The following list of exemplary agents should not be considered exhaustive or limiting.

The drug will be contained within the reservoir. In some cases, the reservoir is a primary container that is either filled or prefilled with a drug for treatment. The primary container can be a vial, cartridge, or prefilled syringe.

In some embodiments, the reservoir of the drug delivery device may be filled with, or the device may be used with, a colony stimulating factor, such as granulocyte colony stimulating factor (G-CSF). Such G-CSF agents include Neulasta® (pegfilgrastim, PEGylated filgastrim, PEGylated G-CSF, PEGylated hu-Met-G-CSF) and Neupogen® ( filgrastim, G-CSF, hu-MetG-CSF), UDENYCA® (pegfilgrastim-cbqv), Ziextenzo® (LA-EP2006; pegfilgrastim-bmez), or FULPHILA ( pegfilgrastim-bmez).

In other embodiments, the drug delivery device may contain or be used with an erythropoiesis stimulating agent (ESA), which may be in liquid or lyophilized form. ESA is any molecule that stimulates erythropoiesis. In some embodiments, the ESA is an erythropoietic stimulating protein. As used herein, "erythropoiesis-stimulating protein" refers to any protein that directly or indirectly causes activation of an erythropoietin receptor, e.g., by binding to the receptor and causing dimerization of the receptor. means protein. Erythropoietic stimulating proteins include erythropoietin and its variants, analogs, or derivatives that bind to and activate the erythropoietin receptor; antibodies that bind to and activate the erythropoietin receptor; or erythropoietin receptors. Examples include peptides that bind to and activate the body. Erythropoiesis-stimulating proteins include Epogen (registered trademark) (epoetin alfa), Aranesp (registered trademark) (darbepoetin alfa), Dynepo (registered trademark) (epoetin delta), Mircera (registered trademark) (methoxypolyethylene glycol-epoetin beta). , Hematide®, MRK-2578, INS-22, Retacrit® (epoetin zeta), Neorecormon® (epoetin beta), Silapo® (epoetin zeta), Binocrit® (epoetin alfa), epoetin alfa Hexal, Abseamed® (epoetin alfa), Ratioepo® (epoetin theta), Eporatio® (epoetin theta), Biopoin® (epoetin theta), epoetin including, but not limited to, epoetin alpha, epoetin beta, epoetin iota, epoetin omega, epoetin delta, epoetin zeta, epoetin theta, and epoetin delta, pegylated erythropoietin, carbamylated erythropoietin, and molecules or variants or analogs thereof. Not done.

Among certain exemplary proteins are those described below, including fusions, fragments, analogs, variants, or derivatives thereof: fully humanized and human OPGL-specific antibodies, particularly fully humanized and human OPGL-specific antibodies; OPGL-specific antibodies (also referred to as RANKL-specific antibodies, peptibodies, etc.), peptibodies, related proteins, etc., including humanized monoclonal antibodies; myostatin-binding proteins, peptibodies, related proteins, etc., including myostatin-specific peptibodies; in particular, IL- IL-4 receptor-specific antibodies, peptibodies, related proteins, etc. that inhibit activity mediated by binding of IL-4 and/or IL-13 to the receptor; interleukin 1-receptor 1 (“IL1-R1”) Specific antibodies, peptibodies, related proteins, etc.; Ang2-specific antibodies, peptibodies, related proteins, etc.; NGF-specific antibodies, peptibodies, related proteins, etc.; CD22-specific antibodies, peptibodies, related proteins, etc., especially binding to human-mouse monoclonal hLL2 kappa chain human-mouse monoclonal hLL2 gamma chain disulfide dimer, including in particular human CD22-specific IgG antibodies, such as the human CD22-specific fully humanized antibody of epratuzumab (CAS Registration No. 501423-23-0) human CD22-specific antibodies, such as, but not limited to, humanized and fully human monoclonal antibodies; including, but not limited to, anti-IGF-1R antibodies; 1 receptor-specific antibodies, peptibodies, and related proteins; including, but not limited to, fully human IgG2 monoclonal antibodies that bind to epitopes of the first immunoglobulin-like domain of B7RP-1; B-7-related protein 1-specific antibodies, peptibodies, related proteins, including, but not limited to, those that inhibit the interaction of B7RP-1 with its natural receptor, ICOS, on activated T cells. (also referred to as "B7RP-1" and B7H2, ICOSL, B7h, and CD275); particularly humanized monoclonal antibodies, including, but not limited to, HuMax IL-15 antibodies and related proteins, such as 145c7. , IL-15 specific antibodies, peptibodies, related proteins, etc.; TALL-1 specific antibodies, peptibodies, related proteins, etc., as well as other TALL-specific binding proteins; parathyroid hormone (“PTH”) specific antibodies, peptibodies, related proteins, etc.; thrombopothien receptor (“TPO-R”) specific Antibodies, peptibodies, related proteins, etc.; those targeting the HGF/SF:cMet axis (HGF/SF:c-Met), such as fully human monoclonal antibodies that neutralize hepatocyte growth factor/dispersion factor (HGF/SF) TRAIL-R2 specific antibodies, peptibodies, related proteins, etc.; Activin A-specific antibodies, peptibodies, proteins, etc.; TGF-beta specific antibodies, peptibodies, including; amyloid-beta protein specific antibodies, peptibodies, related proteins, etc.; c-Kit specific antibodies, peptibodies, including but not limited to proteins that bind c-Kit and/or other stem cell factor receptors; Related proteins, etc.; OX40L-specific antibodies, peptibodies, related proteins, etc., including but not limited to proteins that bind OX40L and/or other ligands of the OX40 receptor; Activase® (alteplase, tPA); Aranesp (registered trademark); Trademark) (darbepoetin alfa), erythropoietin [30-asparagine, 32-threonine, 87-valine, 88-asparagine, 90-threonine], darbepoetin alfa, novel hematopoietic stimulating protein (NESP); Epogen (registered trademark) (epoetin alfa, GLP-1, Avonex® (interferon beta-1a); Bexxar® (tositumomab, anti-CD22 monoclonal antibody); Betaseron® (interferon-beta); Campath® (Alemtuzumab, anti-CD52 monoclonal antibody); Dynepo® (epoetin delta); Velcade® (bortezomib); MLN0002 (anti-α4β7 mAb); MLN1202 (anti-CCR2 chemokine receptor mAb); Enbrel® (etanercept, TNF receptor/Fc fusion protein, TNF blocker); Eprex® (epoetin alfa); Erbitux® (cetuximab, anti-EGFR/HER1/c-ErbB-1); Genotropin® ) (somatropin, human growth hormone); Herceptin® (trastuzumab, anti-HER2/neu (erbB2) receptor mAb); Kanjinti™ (trastuzumab-anns) anti-HER2 monoclonal antibody, Herceptin® bio Similar or another product containing trastuzumab for the treatment of breast or gastric cancer; Humatrope® (somatropin, human growth hormone); Humira® (adalimumab); Vectibix® (panitumumab) , Xgeva® (denosumab), Prolia® (denosumab), immunoglobulin G2 human monoclonal antibody against RANK ligand, Enbrel® (etanercept, TNF receptor/Fc fusion protein, TNF blocker), Nplate® (romiprostim), rilotumumab, ganitumab, conatumumab, brodalumab, insulin in solution; Infergen® (interferon alfacon-1); Natrecor® nesiritide; recombinant human sodium type B Diuretic peptide (hBNP); Kineret® (anakinra); Leukine® (sargamostim, rhuGM-CSF); LymphoCide® (epratuzumab, anti-CD22 mAb); Benlysta® (lymphostat B) , belimumab, anti-BlyS mAb); Metalyse® (tenecteplase, t-PA analog); Mircera® (methoxypolyethylene glycol-epoetin beta); Mylotarg® (gemtuzumab ozogamicin) ); Raptiva® (efalizumab); Cimzia® (certolizumab pegol, CDP 870); Soliris® (eculizumab); pexelizumab (anti-complement C5); Numax® (MEDI -524); Lucentis® (ranibizumab); Panorex® (17-1A, edrecolomab); Trabio® (lerdelimumab); TheraCim hR3 (nimotuzumab); Omnitarg (pertuzumab, 2C4); Osidem ( OvaRex® (B43.13); Nuvion® (vigilizumab); Cantuzumab mertansine (huC242-DM1); NeoRecormon® (epoetin beta); Neumega® (oprelvekin, human interleukin-11); Orthoclone OKT3® (muromonab-CD3, anti-CD3 monoclonal antibody); Procrit® (epoetin alfa); Remicade® (infliximab, Anti-TNFα monoclonal antibody); Reopro® (abciximab, anti-GP lIb/Ilia receptor monoclonal antibody); Actemra® (anti-IL6 receptor mAb); Avastin® (bevacizumab), HuMax-CD4 (zanolimumab); Mvasi(TM) (bevacizumab-awwb); Rituxan(R) (rituximab, anti-CD20 mAb); Tarceva(R) (erlotinib); Roferon-A(R)-(interferon alpha-2a) ; Simulect® (basiliximab); Prexige® (lumiracoxib); Synagis® (palivizumab); 145c7-CHO (anti-IL15 antibody, see US Pat. No. 7,153,507) Tysabri® (natalizumab, anti-α4 integrin mAb); Valortim® (MDX-1303, anti-anthrax (B. Xolair® (omalizumab); ETI211 (anti-MRSA mAb); IL-1 trap (Fc portion of human IgG1 and both IL-1 receptor components (type I VEGF trap (Ig domain of VEGFR1 fused to IgG1 Fc); Zenapax® (daclizumab); Zenapax® (daclizumab, anti-IL-2Rα mAb) Zevalin® (ibritumomab tiuxetan); Zetia® (ezetimibe); Orencia® (atacicept, TACI-Ig); anti-CD80 monoclonal antibody (galiximab); anti-CD23 mAb (lumiliximab) ; BR2-Fc (huBR3/huFc fusion protein, soluble BAFF antagonist); CNTO 148 (golimumab, anti-TNFα mAb); HGS-ETR1 (mapatuzumab; human anti-TRAIL receptor-1 mAb); HuMax-CD20 (ocrelizumab, anti-TRAIL receptor-1 mAb); CD20 human mAb); HuMax-EGFR (zaltumumab); M200 (volociximab, anti-α5β1 integrin mAb); MDX-010 (ipilimumab, anti-CTLA-4 mAb, and VEGFR-1 (IMC-18F1); anti-BR3 mAb; anti-C C. difficile toxin A and toxin B C mAb MDX-066 (CDA-1) and MDX-1388); anti-CD22 dsFv-PE38 conjugate (CAT-3888 and CAT-8015); anti-CD25 mAb (HuMax -TAC); anti-CD3 mAb (NI-0401); adecatumumab; anti-CD30 mAb (MDX-060); MDX-1333 (anti-IFNAR); anti-CD38 mAb (HuMax CD38); anti-CD40L mAb; anti-Cripto mAb; anti-CTGF Idiopathic pulmonary fibrosis stage 1 fibrogen (FG-3019); anti-CTLA4 mAb; anti-eotaxin 1 mAb (CAT-213); anti-FGF8 mAb; anti-ganglioside GD2 mAb; anti-ganglioside GM2 mAb; anti-GDF-8 human mAb ( MYO-029); anti-GM-CSF receptor mAb (CAM-3001); anti-HepC mAb (HuMax HepC); anti-IFNα mAb (MEDI-545, MDX-198); anti-IGF1R mAb; anti-IGF-1R mAb (HuMax -Inflam); anti-IL12 mAb (ABT-874); anti-IL12/IL23 mAb (CNTO 1275); anti-IL13 mAb (CAT-354); anti-IL2Ra mAb (HuMax-TAC); anti-IL5 receptor mAb; anti-integrin receptor anti-IP10 ulcerative colitis mAb (MDX-1100); BMS-66513; anti-mannose receptor/hCGβ mAb (MDX-1307); anti-mesothelin dsFv-PE38 conjugate (CAT -5001); anti-PD1 mAb (MDX-1106 (ONO-4538)); anti-PDGFRα antibody (IMC-3G3); anti-TGFβ mAb (GC-1008); anti-TRAIL receptor-2 human mAb (HGS-ETR2); TWEAK mAb; anti-V
EGFR/Flt-1 mAb; and anti-ZP3 mAb (HuMax-ZP3).

In some embodiments, the drug delivery device contains romosozumab, brosozumab, BPS 804 (Novartis), Evenity™ (romosozumab-aqqg), romosozumab for the treatment of postmenopausal osteoporosis and/or fracture healing. Other products may include, but are not limited to, sclerostin antibodies, and in other embodiments, monoclonal antibodies (IgG) that bind to human proprotein convertase subtilisin/kexin type 9 (PCSK9), or May be used together with these. Such PCSK9-specific antibodies include, but are not limited to, Repatha® (evolocumab) and Praluent® (alirocumab). In other embodiments, the drug delivery device may contain or be used with rilotumumab, bixaromer, trebananib, ganitumab, conatumumab, motesanibuniphosphate, brodalumab, vidupiprant, or panitumumab. In some embodiments, the reservoir of the drug delivery device includes, but is not limited to, OncoVEXGALV/CD; OrienX010; G207, 1716; NV1020; NV12023; NV1034; IMLYGIC® (Talimogene Rahparepvec) or another oncolytic HSV may be loaded or the device can be used with these. In some embodiments, the drug delivery device may contain or be used with endogenous tissue inhibitors of metalloproteinases (TIMPs), such as, but not limited to, TIMP-3. In some embodiments, the drug delivery device contains Aimovig® (erenumab-aooe), anti-human CGRP-R (calcitonin gene-related peptide type 1 receptor), or erenumab for the treatment of migraine. It may contain or be used in conjunction with another product. Antagonistic antibodies of the human calcitonin gene-related peptide (CGRP) receptor, such as, but not limited to, erenumab, and bispecific antibody molecules that target the CGRP receptor and other headache targets, are also included in the drugs of this disclosure. It may be delivered using a delivery device. In addition, bispecific T cell inducing (BiTE®) molecules such as, but not limited to, BLINCYTO® (blinatumomab) can be used in or with the drug delivery devices of the present disclosure. can. In some embodiments, the drug delivery device may contain or be used with an APJ large molecule agonist, such as, but not limited to, apelin or analogs thereof. In some embodiments, a therapeutically effective amount of anti-thymic stromal lymphopoietic factor (TSLP) or TSLP receptor antibody is used in or in conjunction with the drug delivery devices of the present disclosure. In some embodiments, the drug delivery device is a biosimilar of Avsola™ (infliximab-axxq), an anti-TNF alpha monoclonal antibody, Remicade® (infliximab) (Janssen Biotech, Inc.) or an autoimmune It may contain or be used in conjunction with another product containing infliximab for the treatment of disease. In some embodiments, the drug delivery device comprises Kyprolis® (carfilzomib), (2S)-N-((S)-1-((S)-4-methyl-1-((R)- 2-Methyloxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamide)-4-phenylbutanamide)- It may also contain or be used in conjunction with 4-methylpentanamide, or another product containing carfilzomib for the treatment of multiple myeloma. In some embodiments, the drug delivery device comprises Otezla® (apremilast), N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl) [ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide, or another product containing apremilast for the treatment of various inflammatory diseases. , or may be used in conjunction with this. In some embodiments, the drug delivery device is used to treat secondary hyperparathyroidism (sHPT), such as in patients with Parsabiv™ (ethelcalcetide HCl, KAI-4169) or chronic kidney disease (KD) on hemodialysis. ) may be contained or used in conjunction with another product containing etelcalcetide HCl for the treatment of In some embodiments, the drug delivery device may contain ABP 798 (rituximab), a Rituxan®/MabThera™ biosimilar candidate, or another product containing an anti-CD20 monoclonal antibody. may be used or may be used together. In some embodiments, the drug delivery device comprises a VEGF antagonist, such as a non-antibody VEGF antagonist, and/or a VEGF trap such as aflibercept (Ig domain 2 from VEGFR1 and VEGFR2 fused to the Fc domain of IgG1). may contain or be used in conjunction with Ig domains 3) from In some embodiments, the drug delivery device contains ABP 959 (eculizumab), a biosimilar candidate of Soliris®, or another product containing a monoclonal antibody that specifically binds complement protein C5. or may be used in conjunction with this. In some embodiments, the drug delivery device may house a novel bispecific antibody-peptide conjugate, Rozibafusp alpha (formerly AMG 570), that simultaneously blocks ICOSL and BAFF activity. Or it may be used together with this. In some embodiments, the drug delivery device comprises omecamtibumecarbil, a small molecule selective cardiac myosin activator, or myotrope, or a small molecule selective cardiac myosin activator that directly targets the contractile machinery of the heart. It may also contain or be used in conjunction with another product containing the agent. In some embodiments, the drug delivery device may house sotorasib (formerly known as AMG 510), a KRAS ^G12C small molecule inhibitor, or another product containing a KRAS ^G12C small molecule inhibitor. Or it may be used together with this. In some embodiments, the drug delivery device comprises tezepelumab, a human monoclonal antibody that inhibits the action of thymic stromal lymphopoietic factor (TSLP), or another product containing a human monoclonal antibody that inhibits the action of TSLP. It may contain or be used in conjunction with. In some embodiments, the drug delivery device comprises AMG 714, a human monoclonal antibody that binds interleukin-15 (IL-15), or another human monoclonal antibody that binds interleukin-15 (IL-15). may contain or be used in conjunction with other products. In some embodiments, the drug delivery device comprises AMG 890 that reduces lipoprotein(a), also known as Lp(a), small interfering RNA (siRNA), or small interfering RNA that reduces lipoprotein(a). (siRNA) may be contained or used in conjunction with another product containing (siRNA). In some embodiments, the drug delivery device contains ABP 654 (a human IgG1 kappa antibody), a biosimilar candidate of Stelara®, or a human IgG1 kappa antibody and/or a human cytokine interleukin (IL). -12 and other products that bind to the p40 subunit of IL-23 may be included or used in conjunction with the present invention. In some embodiments, the drug delivery device is a biosimilar candidate of Amjevita™ or Amgevita™ (formerly ABP 501) (mab anti-TNF human IgG1), Humira®, or a human mab anti- It may also contain or be used in conjunction with another product containing TNF human IgG1. In some embodiments, the drug delivery device comprises AMG 160, or a half-life extended (HLE) anti-prostate-specific membrane antigen (PSMA) x anti-CD3 BiTE® (bispecific T cell engager) construct. may contain or be used in conjunction with another product containing. In some embodiments, the drug delivery device may contain or contain another product containing AMG 119 or delta-like ligand 3 (DLL3) CAR T (chimeric antigen receptor T cell) cell therapy. May be used with. In some embodiments, the drug delivery device may contain or contain another product containing AMG 119 or delta-like ligand 3 (DLL3) CAR T (chimeric antigen receptor T cell) cell therapy. May be used with. In some embodiments, the drug delivery device may contain or be used in conjunction with AMG 133, or another product containing a gastric inhibitory polypeptide receptor (GIPR) antagonist and a GLP-1R agonist. Good too. In some embodiments, the drug delivery device may contain or be used in conjunction with AMG 171, or another product containing a growth differentiation factor 15 (GDF15) analog. In some embodiments, the drug delivery device may contain or be used in conjunction with AMG 176, or another product containing a small molecule inhibitor of myeloid cell leukemia 1 (MCL-1). good. In some embodiments, the drug delivery device may house AMG 199 or another product containing a half-life extension (HLE) bispecific T cell engager construct (BiTE®). , or may be used in conjunction with this. In some embodiments, the drug delivery device was designed to selectively activate the interleukin 21 (IL-21) pathway in AMG 256, or programmed cell death-1 (PD-1) positive cells. Other products containing anti-PD-1xIL21 muteins and/or IL-21 receptor agonists may be included or used in conjunction with them. In some embodiments, the drug delivery device may house AMG 330 or another product containing an anti-CD33 x anti-CD3 BiTE® (bispecific T cell engager) construct. Or it may be used together with this. In some embodiments, the drug delivery device is AMG 404, or another product containing a human anti-programmed cell death-1 (PD-1) monoclonal antibody that is being investigated as a treatment for patients with solid tumors. It may contain or be used in conjunction with. In some embodiments, the drug delivery device comprises AMG 427, or a half-life extended (HLE) anti-FMS-like tyrosine kinase 3 (FLT3) x anti-CD3 BiTE® (bispecific T cell engager) construct. may contain or be used in conjunction with another product containing. In some embodiments, the drug delivery device may contain or be used in conjunction with AMG 430 or another product containing an anti-Jagged-1 monoclonal antibody. In some embodiments, the drug delivery device is AMG 506, or another product containing a multispecific FAPx4-1BB targeting DARPin® biologic that is being investigated as a treatment for solid tumors. It may contain or be used in conjunction with. In some embodiments, the drug delivery device may house AMG 509, or another product containing a bivalent T cell engager and designed using XmAb® 2+1 technology. Or it may be used together with this. In some embodiments, the drug delivery device comprises AMG 562, or an extended half-life (
HLE) CD19xCD3 BiTE® (bispecific T cell engager) construct may be contained or used in conjunction with another product containing the construct. In some embodiments, the drug delivery device may contain or be used in conjunction with another product containing Effa Valuquin Alfa (formerly AMG 592) or an IL-2 mutein Fc fusion protein. good. In some embodiments, the drug delivery device comprises AMG 596, or another product containing a CD3x epidermal growth factor receptor vIII (EGFRvIII) BiTE® (bispecific T cell engager) molecule. It may be contained or used in conjunction with. In some embodiments, the drug delivery device comprises AMG 673, or another product containing a half-life extension (HLE) anti-CD33 x anti-CD3 BiTE® (bispecific T cell engager) construct. It may be contained or used in conjunction with. In some embodiments, the drug delivery device comprises AMG 701, or a half-life extension (HLE) anti-B cell maturation antigen (BCMA) x anti-CD3 BiTE® (bispecific T cell engager) construct. It may contain or be used in conjunction with another product containing it. In some embodiments, the drug delivery device comprises AMG 757, or a half-life extension (HLE) anti-delta-like ligand 3 (DLL3) x anti-CD3 BiTE® (bispecific T cell engager) construct. It may contain or be used in conjunction with another product containing it. In some embodiments, the drug delivery device comprises AMG 910, or half-life extended (HLE) epithelial cell tight junction constituent protein claudin 18.2xCD3 BiTE® (bispecific T cell engager). It may contain or be used in conjunction with another product containing the construct.

Although drug delivery devices, assemblies, components, subsystems, and methods have been described in terms of exemplary embodiments, they are not limited thereto. The detailed description is to be construed as an example only and does not describe all possible embodiments of the present disclosure. Although many alternative embodiments may be implemented using either current technology or technology developed after the filing date of this patent, such embodiments are still incorporated herein. It is within the scope of the claims that define the invention as disclosed.

Those skilled in the art can make various modifications, changes, and combinations to the embodiments described above without departing from the spirit and scope of the invention disclosed herein, and such modifications, changes, It will be understood that combinations and combinations thereof are to be considered within the scope of the inventive concept.

Claims (44)

A carton for storing drugs,
a bottom box having a bottom wall, a first side wall, a second side wall, a back wall, and a front wall;
a lid coupled to the bottom box and movable between an open position and a closed position;
a release tab comprising a portion of one of the lid and the bottom box and defined by a perforation line in the one of the lid and the bottom box;
an adhesive disposed on at least a portion of the release tab to selectively bond the lid and the bottom box;
When the lid is in the closed position, the release tab is secured to one of the lid and the bottom box via the perforation line and to the other of the lid and the bottom box via the adhesive. has been
When the lid is in the unsealed position, the release tab is separated from one of the lid and the bottom box along the perforation line and fixed to the other of the lid and the bottom box via the adhesive. Carton. The carton of claim 1, wherein the lid comprises a top wall and a front lid. 3. The carton of claim 2, wherein the front lid is located within the bottom box when the lid is in the closed position. 2. The lid comprises a third side wall adjacent to the first side wall, a fourth side wall adjacent to the second side wall, and a second front wall adjacent to the first front wall. carton as described in. A carton according to any one of claims 1 to 4, wherein the release tab is a push tab that releases the release tab from one of the lid and the bottom box. The release tab is a push tab with a first portion partially disengaging the release tab from one of the lid and the bottom box, and a second portion disengaging the remainder of the release tab from the lid and the bottom box. 6. A box according to any one of claims 1 to 5, comprising said first part and said second part hinged to said first part so as to be a pull tab for removal from one of the boxes. carton. an upper edge of the first front wall such that when the lid is in the closed position at least one tab engages at least one latch feature to resist movement of the lid to the opened position; 7. A carton according to any preceding claim, further comprising the at least one tab carried by the at least one tab and the at least one latch feature carried by the inner surface of the second front wall. 8. The at least one latching feature comprises a flap hinged to either the third or fourth side wall and secured to the inner surface of the second front wall. Carton as described. A carton according to any preceding claim, wherein the adhesive comprises an adhesive label. 10. The carton of claim 9, wherein the adhesive label is attached to the release tab and to one of the lid and the bottom wall of the bottom box. 11. The carton of claim 10, wherein the release tab includes a kiss cut to improve securing between the release tab and the adhesive label. 12. A carton according to claim 10 or 11, wherein one of the lid and the bottom box includes a kiss cut to improve the fixation between the one of the lid and the bottom box and the adhesive label. A carton according to any one of the preceding claims, wherein the carton is made from a single piece of material. the carton includes a first exterior finish having a first texture; the release tab includes a second exterior finish having a second texture; and the first texture is different from the second texture. A carton according to any one of claims 1 to 13, which is different. the first front wall includes a cutout adjacent an upper edge of the first front wall such that the first front wall exhibits increased flexibility relative to the second front wall; Carton according to any one of claims 3 to 14. A carton according to any preceding claim, further comprising a storage cavity disposed within the bottom box and a drug delivery device containing a medicament disposed within the storage cavity. A carton for storing drugs,
a bottom box having a bottom wall, a first side wall, a second side wall, a back wall, and a first front wall;
a lid coupled to the bottom box and movable between an open position and a closed position, the bottom box being closed by the lid when the lid is in the closed position;
a release tab comprising a portion of the lid and one of the front walls and defined by a perforation line in the lid and the one of the first front walls;
an adhesive disposed on at least a portion of the release tab and selectively bonding the lid and the first front wall;
when the lid is in the closed position, the release tab is secured to one of the lid and the first front wall via an adhesive label;
When the lid is in the unsealed position, the release tab is separated from one of the lid and the first front wall along the perforation line and is attached to the lid and the first front wall via the adhesive. Carton, fixed to the other side of the front wall. 18. The carton of claim 17, wherein the lid comprises a top wall and a front lid. 19. The carton of claim 18, wherein the front lid is located within the bottom box when the lid is in the closed position. 5. The lid comprises a third side wall adjacent to the first side wall, a fourth side wall adjacent to the second side wall, and a second front wall adjacent to the first front wall. 17. The carton according to item 17. 21. According to any one of claims 17 to 20, the release tab is a push tab for disengaging the release tab from one of the lid, the first front wall, and the second front wall. Carton as described. the release tab is a push tab with a first portion partially disengaging the release tab from one of the lid, the first front wall, and the second front wall; the first portion, and the first portion, such that the portion is a pull tab that releases the remainder of the release tab from one of the lid, the first front wall, and the second front wall. A carton according to any one of claims 17 to 21, comprising said second part hinged to a part. an upper edge of the first front wall such that when the lid is in the closed position at least one tab engages at least one latch feature to resist movement of the lid to the opened position; 23. A carton according to any one of claims 17 to 22, further comprising the at least one tab carried by the at least one tab and the at least one latch feature carried by the inner surface of the second front wall. 24. The method of claim 23, wherein the at least one latching feature comprises a flap hinged to either the third or fourth side wall and secured to the inner surface of the second front wall. Carton as described. A carton according to any one of claims 17 to 24, wherein the adhesive comprises an adhesive label comprising a tamper evident seal. 25. The adhesive label is attached to the release tab and to one of the lid, the first front wall, the second front wall, and the bottom wall of the bottom box. carton as described in. A carton according to any one of claims 17 to 26, wherein the release tab includes a kiss cut to improve the fixation between the release tab and the adhesive label. A carton according to any one of claims 17 to 27, wherein the carton is made from a single piece of material. the carton includes a first exterior finish having a first texture; the release tab includes a second exterior finish having a second texture; and the first texture is different from the second texture. A carton according to any one of claims 17 to 28, which is different. the first front wall includes a cutout adjacent an upper edge of the first front wall such that the first front wall exhibits increased flexibility relative to the second front wall; Carton according to any one of claims 18 to 29. 31. A carton according to any one of claims 17 to 30, further comprising a storage cavity disposed within the bottom box and a drug delivery device disposed within the storage cavity containing a medicament. A carton for storing drugs,
a bottom box having a bottom wall, a first side wall, a second side wall, a back wall, and a front wall;
an upper part movable between an open position and a closed position, the bottom box comprising a top wall and a second front wall adjacent the first front wall, the upper part being in the closed position; an upper portion, at one time being positioned adjacent to the upper portion;
a release tab comprising a portion of the second front wall and defined between a bottom edge of the second front wall and a perforation line of the second front wall;
the release tab is secured to the bottom box via an adhesive label when the top is in the open position and the closed position;
The carton, wherein the release tab is separated from the second front wall along the perforation line when the top is in the unsealed position. 33. The carton of claim 32, wherein the release tab is a push tab that releases the release tab from the second front wall. The release tab is a push tab with a first portion partially disengaging the release tab from the second front wall, and a second portion disengaging the remainder of the release tab from the second front wall. 33. The carton of claim 32, comprising the first portion and the second portion hinged to the first portion so as to be a release pull tab. A top edge of the first front wall such that when the top is in the closed position, at least one tab engages at least one latch feature to resist movement of the top to the unsealed position. 35. A carton according to any one of claims 32 to 34, further comprising the at least one tab carried by and the at least one latch feature carried by an inner surface of the second front wall. the at least one latching feature is hinged to either a third sidewall hinged to the top or a fourth sidewall hinged to the top; 36. A carton according to claim 35, comprising a flap secured to the inner surface. A carton according to any one of claims 32 to 36, wherein the release tab is secured to the bottom box via adhesive. 38. A carton according to any one of claims 32 to 37, wherein the release tab is secured to the bottom box with an adhesive label attached to the release tab and the bottom box. 39. The carton of claim 38, wherein the adhesive label is attached to the release tab and the bottom wall of the bottom box. 40. The carton of claim 39, wherein the release tab includes a kiss cut to improve securing between the release tab and the adhesive label. 41. A carton according to claim 39 or 40, wherein the bottom wall of the bottom box includes a kiss cut to improve fixation between the bottom box and the adhesive label. the carton includes a first exterior finish having a first texture; the release tab includes a second exterior finish having a second texture; and the first texture is different from the second texture. A carton according to any one of claims 32 to 41, which is different. the first front wall includes a cutout adjacent an upper edge of the first front wall such that the first front wall exhibits increased flexibility relative to the second front wall; Carton according to any one of claims 32 to 42. 44. A carton according to any one of claims 32 to 43, further comprising a storage cavity disposed within the bottom box and a drug delivery device containing a medicament disposed within the storage cavity.

Images